Mathematical modelling and projecting the second wave of COVID-19 pandemic in Europe

A second wave of the COVID-19 pandemic has spurred in most of the European countries since the summer of 2020, and currently it remains uncertain when and how this can be fully controlled. In this study, we aim to nowcast and forecast the possible development of the second COVID-19 wave in representative European countries including Spain, France and the Netherlands by mathematical modelling.

We adopted a SPMILHRD model based on the modification of the classic epidemic compartmental model SEIR (online supplemental methods; figure 1). How rapid an epidemic can spread largely depends on the reproductive number \( R_t \). To better understand the epidemic spread, we estimated the time-varying reproduction number in these countries, resulting in gradual reduction of \( R_t \) until below 1 during April and May and the control of local epidemics. However, we observed the time-varying reproduction number has continuously exceeded 1 since 22 June in Spain, 26 June in France and 09 July in the Netherlands, with the rising of incident cases.

Enhanced control measures were subsequently implemented resulting in reduction of \( R_t \) value until below 1 in November. The overall dynamics of epidemic spread are very similar in these three European countries. Our nowcasting on the estimated total or detected cumulative cases and the total or detected ongoing infections of the second wave by 30 November are well in line with the reported real-world cases from these three countries (figure 2B).

We next forecasted the possible development of the second COVID-19 wave from 1 December 2020 to 28 February 2021 (figure 2C). In reality, a prolonged ‘lockdown’ is hardly possible to be implemented in Europe, in particular given that Christmas and New Year festivals are approaching. If control measures would be weakened with the transmission rate, for example, reverting to the situation in October, the total infections would reach 1.74 times in Spain, 3.87 times in France, 3.81 times in the Netherlands after 3 months as compared with the case numbers on 30 November (figure 2C). Furthermore, the rate of detecting infected cases would be reduced, which poses more challenges for controlling the transmission.

Of note, the peak of daily new confirmed cases in the second wave is much higher than the one in the first wave in the spring of 2020 in Europe, and these differences are about 10 times in France and the Netherlands. Thus, reinforcing restriction measures is urgently required to mitigate the second wave in Europe. If the level of current measures can be maintained, the probable cumulative infections would be reduced by 33.2% (95% CI 32.9% to 33.4%) in Spain, 70.2% (95% CI 70.0% to 70.3%) in France and 66.7% (95% CI 66.3% to 67.0%) in the Netherlands in the coming 3 months since 1 December, as compared with the scenario of weakened control measures. In total, 7 million infections would be avoided in

Figure 1  Graphical scheme representing the interactions among different compartments in the SPMILHRD model. In the mathematical model, S: susceptible, uninfected; P: infected, infectious, undetected, no symptom; M: infected, infectious, detected, no symptom; I: actively infected, infectious, undetected, with symptom; L: actively infected, infectious, detected, with symptom; H: actively infected, hospitalised, ailing, with severe symptom, life-threatening, quarantined; R: recovered or healed; D: dead; \( \beta \): transmission rate; \( \mu \): the proportion of symptoms; \( \eta \): the proportion of diagnosis; \( h \): admission rate; \( r, r', r'' \): recovery rate; \( \sigma \): death rate.
these three countries (figure 2C). Our forecasting should serve as an urgent wake-up call to the authorities and the general public to take swift actions in responding to this second wave in Europe.

Qinyue Zheng,1 Xinwei Wang,2 Chunbing Bao,1 Zhongren Ma,3 Qiuwei Pan3,4

1School of Management, Shandong Key Laboratory of Social Supernetwork Computation and Decision Simulation, Shandong University, Jinan, Shandong, China
2Department of Engineering Mechanics, State Key Laboratory of Structural Analysis for Industrial Equipment, Dalian University of Technology, Dalian, Liaoning, China
3Biomedical Research Center, Northwest Minzu University, Lanzhou, Gansu, China
4Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, South Holland, The Netherlands

Correspondence to Dr Qiuwei Pan, Erasmus MC-University Medical Center, Rotterdam, South Holland, The Netherlands; q.pan@erasmusmc.nl and Professor Zhongren Ma, Biomedical Research Center, Northwest Minzu University, Lanzhou, China; mzn@xbmu.edu.cn

Contributors QP and QZ contributed to project conceptualisation. QZ, QP and XW built the model. QZ, QP, CB and MZ designed the scenario settings. QZ, QP, CB and XW performed effectiveness analysis. QZ wrote the manuscript. QP, XW, CB and MZ edited the manuscript. QP and MZ supervised the project. All authors approved the manuscript.

Funding The authors acknowledge the support by the Changjiang Scholars and Innovative Research Team in University grant (no. IRT_17R88) from the Ministry of Education of the People’s Republic of China to MZ, and the National Natural Science Foundation of China grant (no. 71901132) to CB.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Author note Zhongren Ma and Qiuwei Pan share joint correspondence in this work.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others...
REFERENCES

